Triton Wealth Management PLLC Purchases 199 Shares of Johnson & Johnson (NYSE:JNJ)

Triton Wealth Management PLLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,578 shares of the company’s stock after purchasing an additional 199 shares during the quarter. Johnson & Johnson makes up approximately 0.4% of Triton Wealth Management PLLC’s portfolio, making the stock its 29th largest holding. Triton Wealth Management PLLC’s holdings in Johnson & Johnson were worth $741,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Thrive Wealth Management LLC raised its stake in shares of Johnson & Johnson by 0.8% during the 3rd quarter. Thrive Wealth Management LLC now owns 23,739 shares of the company’s stock valued at $3,847,000 after purchasing an additional 189 shares during the period. AMI Investment Management Inc. increased its position in shares of Johnson & Johnson by 4.8% during the third quarter. AMI Investment Management Inc. now owns 23,885 shares of the company’s stock valued at $3,871,000 after buying an additional 1,090 shares during the period. HBW Advisory Services LLC lifted its holdings in shares of Johnson & Johnson by 144.8% in the third quarter. HBW Advisory Services LLC now owns 6,393 shares of the company’s stock worth $1,036,000 after buying an additional 3,782 shares in the last quarter. LifePlan Financial LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $202,000. Finally, MRA Advisory Group grew its stake in Johnson & Johnson by 8.6% during the third quarter. MRA Advisory Group now owns 2,713 shares of the company’s stock valued at $440,000 after acquiring an additional 214 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

JNJ traded down $0.21 during trading on Friday, hitting $160.29. 5,331,694 shares of the stock traded hands, compared to its average volume of 7,091,981. The firm has a market capitalization of $385.77 billion, a P/E ratio of 9.99, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a 50-day moving average of $162.60 and a 200 day moving average of $154.33.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the company posted $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, September 30th. TD Securities lowered their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 20th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.